- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07572578
Radicle Women's HealthTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes Among Women Experiencing Menopausal Symptoms
Radicle Women's HealthTM: A Randomized, Double-Blind, Placebo- Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes Among Women Experiencing Menopausal Symptoms
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
Del Mar, California, Forenede Stater, 92014
- Radicle Science Inc.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
3.1 Inclusion
Participants must meet all the following criteria:
Adults, 35-60 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
- Assigned sex at birth is female
- Experience at least two menopausal symptoms
- Resides in the United States
- Has the opportunity for at least 30% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
3.2 Exclusion
Individuals who report any of the following during screening may be excluded from participation:
- Report being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English at a 7th grade level
- Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
- NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
- Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
- Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk
- Lack of reliable daily access to the internet
- Reports surgical menopause/bilateral oophorectomy
- Reports taking HRT or prescription menopausal products
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo Control
Fatigue Product Placebo Control
|
Participants will use their Fatigue Product Placebo Control as directed for a period of 6 weeks.
|
|
Eksperimentel: Active Product 1
Fatigue Active Product 1
|
Participants will use their Fatigue Active Product 1 as directed for a period of 6 weeks.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Chang in fatigue
Tidsramme: 7 weeks
|
Change in fatigue: Difference in rates of change over time in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue)
|
7 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ændring i kognitiv funktion
Tidsramme: 7 uger
|
Ændring i kognitiv funktion: Forskel i ændringer over tid i kognitiv funktionsscore som vurderet af PROMIS kognitiv funktion 8A (skala 8-40; hvor lavere score svarer til dårligere kognitiv funktion)
|
7 uger
|
|
Ændring i følelser af angst
Tidsramme: 7 uger
|
Ændring i angstfølelse: Forskel mellem ændringer over tid i angstfølelsesscore som vurderet ved PROMIS Angst 8A (skala 8-40; med højere score svarende til mere alvorlig angst)
|
7 uger
|
|
Change in menopausal quality of life
Tidsramme: 7 weeks
|
Change in menopausal quality of life: Difference between rates of change over time in menopausal quality of life score as assessed by Menopause-specific Quality of Life Questionnaire (scale 1-8; where the higher scores correspond to worse menopausal quality of life)
|
7 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Minimal klinisk vigtig forskel (MCID) i kognitiv funktion
Tidsramme: 7 uger
|
Minimal klinisk vigtig forskel (MCID) i kognitiv funktion: Sandsynligheden for at opleve minimal klinisk vigtig forskel i kognitiv funktionsscore vurderet af PROMIS kognitiv funktion 8A (skala 8-40; hvor lavere score svarer til dårligere kognitiv funktion)
|
7 uger
|
|
Minimal klinisk vigtig forskel (MCID) i træthed
Tidsramme: 7 uger
|
Minimal klinisk vigtig forskel (MCID) i træthed: Sandsynligheden for at opleve minimal klinisk vigtig forskel i træthedsscore vurderet af PROMIS Fatigue 8A (skala 8-40; hvor højere score svarer til mere alvorlig træthed)
|
7 uger
|
|
Mindste klinisk vigtige forskel (MCID) i følelser af angst
Tidsramme: 7 uger
|
Mindste klinisk signifikante forskel (MCID) for angstfølelser: Sandsynlighed for at opleve mindste klinisk signifikante forskel i score for angstfølelser vurderet ved PROMIS Angst 8A (skala 8-40; hvor højere scorer svarer til mere alvorlig angst)
|
7 uger
|
|
Minimal clinically important difference (MCID) in menopausal quality of life
Tidsramme: 7 weeks
|
Minimal clinically important difference (MCID) in menopausal quality of life: Likelihood of experiencing minimal clinically important difference in menopausal quality of life score as assessed by Menopause-specific Quality of Life Questionnaire (scale 1-8; where the higher scores correspond to worse menopausal quality of life)
|
7 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Susan Hewlings, Radicle Science
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- RADX_P_2608_DIF
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .